生物技术企业Humacyte, Inc.近日宣布，已正式向以色列监管机构递交其创新产品Symvess®的上市授权申请。该产品旨在应用于血管创伤修复领域，标志着公司在全球市场拓展战略中迈出关键一步。若获批，Symvess®将为临床血管重建手术提供全新解决方案。
生物技术企业Humacyte, Inc.近日宣布，已正式向以色列监管机构递交其创新产品Symvess®的上市授权申请。该产品旨在应用于血管创伤修复领域，标志着公司在全球市场拓展战略中迈出关键一步。若获批，Symvess®将为临床血管重建手术提供全新解决方案。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.